A cancer trial’s unexpected result: Remission in every patient (nytimes.com)

Article summary

A cancer trial has shown unexpected results, with every patient achieving remission. The treatment involves a monoclonal antibody that helps the immune system target and destroy cancer cells. The cost of the treatment is around $100,000 over six months. The trial's success has raised questions about the ethics of withholding treatment from control groups in clinical trials.

Main themes

• cancer treatment
• clinical trials
• medical ethics
• end-of-life care
• healthcare costs
• long-term care insurance
• Medicaid and healthcare policy

What commenters say

• The high cost of the treatment may be justified by its effectiveness, but it raises concerns about accessibility and affordability.
• The ethics of clinical trials are complex, and withholding treatment from control groups can be justified if the treatment is not yet proven to be effective.
• Some people believe that the high cost of medical care, particularly for conditions like cancer and dementia, can lead to difficult end-of-life decisions and financial burdens on families.
• The lack of good options for ending one's life on their own terms can lead to delays and difficulties in making such decisions.
• Long-term care insurance may not be the most financially effective way to plan for future care needs, and Medicaid may be a more viable option for some people.
• The quality of care in Medicaid-funded facilities can be a concern, with some facilities having poor reputations and high staff turnover rates.
• The development of new medical treatments can bring significant benefits, but also raises questions about the sustainability of the healthcare system and the distribution of resources.